What does this research mean for the field?

The novel systemic allosteric STING agonist CRD3874-SI demonstrates manageable safety and preliminary clinical activity, with 0.9mg/kg identified as a biologically active dose in patients with advanced solid tumors. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

The central aim is to assess the safety and maximum tolerated dose of CRD3874-SI in patients with advanced solid tumors.

May 29, 2026Journal of Clinical Oncology

Systemic third generation allosteric STING agonist CRD3874-SI, a novel immunotherapy, in patients with advanced solid tumors: Results from a single-agent phase I study.

View Full Paper

Ask AI

Bookmark

Authors

CKCiara M. KellyMemorial Sloan Kettering Cancer Center MBMonali Banerjee RRReinhard von RoemelingCuradel (United States)

Discussion

Member takes

Implication

Randomized trial assesses safety and efficacy of CRD3874-SI in advanced solid tumors, suggesting further investigation is warranted.

Key Points

The central aim is to assess the safety and maximum tolerated dose of CRD3874-SI in patients with advanced solid tumors.
Single institution, open-label, phase I study of CRD3874-SI.
Administered intravenously once weekly for 2 cycles followed by continuous treatment with a possible week off.
Evaluated through a standard 3+3 dose escalation design.
21 patients treated with a median of 4 prior treatments; 19 evaluable for efficacy.
At dose level 3 (0.9mg/kg), there was one confirmed partial response and 9 stable disease cases.
Low-grade treatment emergent adverse events were observed, primarily fatigue, chills, and nausea.

Cite This Study

Kelly et al. (2026) studied this question.

synapsesocial.com/papers/6a192df7fab5b468c4416eed https://doi.org/10.1200/jco.2026.44.16_suppl.2661

View Full Paper

Ask AI

Bookmark

Systemic third generation allosteric STING agonist CRD3874-SI, a novel immunotherapy, in patients with advanced solid tumors: Results from a single-agent phase I study.

Discussion

Member takes

Implication

Key Points

Cite This Study

Systemic third generation allosteric STING agonist CRD3874-SI, a novel immunotherapy, in patients with advanced solid tumors: Results from a single-agent phase I study.

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider